Prostate Cancer Canada Network

In The News

Well-Done Meat Consumption May Increase Prostate Cancer Risk
Research into the dietary habits of about a thousand men from the Cleveland area has found that a high consumption of meats, especially of red meat prepared by grilling, is positively associated with an increased risk of developing aggressive prostate cancer. This particular study, which was led by Dr. John Witte of the University of California, San Francisco (UCSF), has a number of limitations, but it does add support to other investigations connecting meat consumption with cancer risk.

Toronto researchers speculate regarding a link between prostate cancer and oral contraceptive use
Very preliminary and speculative research, designed to spark further inquires, suggests that there may be a connection between oral contraceptive use and rising rates of prostate cancer. One theory is that the widespread use of birth-control pills in various populations may result in a higher level of estrogen in the environment, which might, in turn, increase prostate cancer risk.

Click For Information Archive

Advocacy

Welcome to the new constituent engagement area of the PCC and PCCN websites where we bring you opportunities to:

Share your experience on topics that will help shape PCC program and services
Contribute to patient awareness and advocacy initiatives
Participate in government led initiatives to incorporate patient voices in federal and provincial recommendations regarding drug coverage

We will regularly post surveys or links of interest to those impacted by prostate cancer in Canada.

If you wish to be notified of new surveys or polls, please let us know by sending an email with the subject heading “Constituent Engagement” to ada.jeffrey@prostatecancer.ca.

Our first survey is a part of the pan-Canadian Oncological Drug review process. The pan-Canadian Oncology Drug Review (pCODR) assesses cancer drugs and makes recommendations to the provinces and territories to guide their drug funding decisions. Established in 2010 by the provincial and territorial Ministries of Health, pCODR is designed to bring consistency and clarity to the assessment of new cancer drugs by looking at both clinical evidence and cost-effectiveness.

Part of the pCODR decision making process incorporates feedback from people who have had experience with the drug under review. As part of our mandate to support initiatives that encourage our community’s voices we have designed a confidential and anonymous survey. It is a time-limited survey open until noon on Friday, August 26^th. The results from this survey will be compiled while maintaining complete respondent confidentiality, and submitted to pCODR on September 6^th.

To take the survey please click here.